We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+6.88%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$142M
AUM Growth
-$26.6M
Cap. Flow
-$33.6M
Cap. Flow %
-23.69%
Top 10 Hldgs %
45.91%
Holding
93
New
28
Increased
12
Reduced
11
Closed
39

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$6.21M
2
MDVN
MEDIVATION, INC.
MDVN
+$5.39M
3
COO icon
Cooper Companies
COO
+$5.28M
4
BSX icon
Boston Scientific
BSX
+$5.2M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.11M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$4.21M
2
BMY icon
Bristol-Myers Squibb
BMY
+$4.16M
3
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$3.31M
4
ARWR icon
Arrowhead Research
ARWR
+$3.04M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$2.71M

Sector Composition

Rank Sector Weight
1 Healthcare 59.79%
2 Technology 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRNE
76
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-30,000
Closed -$385K
LCI
77
DELISTED
Lannett Company, Inc.
LCI
– –
-10,000
Closed -$1.43M
EPZM
78
DELISTED
Epizyme, Inc
EPZM
– –
-45,000
Closed -$1.02M
HSTO
79
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-1,100
Closed -$1.79M
ATRS
80
DELISTED
Antares Pharma, Inc.
ATRS
– –
-250,000
Closed -$875K
FLXN
81
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-40,000
Closed -$658K
HZNP
82
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-130,000
Closed -$1.97M
NXTM
83
DELISTED
NxStage Medical Inc.
NXTM
– –
-62,500
Closed -$796K
RXDX
84
DELISTED
Ignyta, Inc.
RXDX
– –
-23,500
Closed -$195K
TEAR
85
DELISTED
TearLab Corporation
TEAR
– –
-12,500
Closed -$845K
AEGR
86
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-100,000
Closed -$4.62M
KYTH
87
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-25,000
Closed -$994K
FURX
88
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
– –
-27,500
Closed -$2.39M
CHTP
89
CALL
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
– –
-300,000
Closed -$1.66M
CHTP
90
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
– –
-600,000
Closed -$3.31M
ETRM
91
DELISTED
EnteroMedics Inc.
ETRM
– –
-381
Closed -$728K
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Ghost Tree Capital held 93 positions worth $142M, down 16% from $168M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ghost Tree Capital withdrew a net $33.6M in Q2 2014, closing 39 positions and reducing 11 holdings. Its most notable exit was Prothena Corp, an estimated $4.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 45% a quarter earlier, followed by Technology.

Against the trend, Ghost Tree Capital opened a new position in Allergan plc worth $6.69M.

  • Ghost Tree Capital's largest Q2 2014 buy was Allergan plc: 30,000 shares worth $6.69M.
  • Ghost Tree Capital added most to AtriCure in Q2 2014, an estimated $2.33M increase.
  • Ghost Tree Capital's biggest Q2 2014 reduction was Avadel Pharmaceuticals, cutting an estimated $2.71M.
  • Ghost Tree Capital fully exited Prothena Corp in Q2 2014, selling an estimated $4.21M.
  • Ghost Tree Capital's ten largest holdings make up 46% of its $142M portfolio in Q2 2014.
  • Ghost Tree Capital opened 28 new positions and closed 39 in Q2 2014.
  • Ghost Tree Capital's portfolio value fell 16% quarter-over-quarter to $142M.

Based on Ghost Tree Capital's 13F filing for Q2 2014, filed 14 Aug 2014.